Meta description: EpiBiologics raises $107 million in Series B funding led by Johnson & Johnson’s and Google Ventures’ investment arms, driving its lead oncology program toward clinical trials.
Protein degradation specialist EpiBiologics has closed a $107 million Series B funding round, with Johnson & Johnson’s venture capital arm and Google Ventures co-leading the investment. This latest capital injection positions the biotech to accelerate its clinical entry and strengthen its pipeline of bispecific antibodies in oncology and immunology. Investors, founders, and strategic partners will want to follow how this funding shifts the competitive landscape in targeted protein degradation.
How was the Series B structured?
The $107 million Series B places EpiBiologics among the better-funded private biotech companies focused on protein degradation. The round was co-led by JJDC, the venture capital arm of Johnson & Johnson, and Google Ventures. This co-lead structure highlights both strategic and financial interest from diverse sectors, combining healthcare expertise with technology-driven investment capacity.
The funds are earmarked for advancing EpiBiologics’ lead program, EPI-326, into first-in-human studies. The initial clinical focus will be on non-small cell lung cancer and head and neck squamous cell carcinoma, with trials expected to start in early 2026. The company also intends to use part of the capital to expand its research pipeline targeting disease-driving extracellular proteins in multiple therapeutic areas.
Who are the investors backing this round?
Beyond the co-leads, the round attracted a mix of returning and new investors, showing continued confidence from prior backers and fresh interest from prominent funds. Returning participants include Polaris Partners, Digitalis Ventures, Taiho Ventures, Vivo Capital, Codon Capital, and Mission BioCapital. Among the new entrants, Novartis Venture Fund took a stake for the first time.
The diverse investor base spans large pharmaceutical corporate venture arms, established biotech-focused funds, and technology sector capital. This blend gives EpiBiologics access to varied strategic expertise and networks that could aid in future partnerships, licensing, or commercialization efforts.
What does this mean for growth?
From a growth standpoint, this Series B exceeds the company’s prior Series A of $50 million raised in 2023. The jump in funding scale suggests increased investor conviction in the market opportunity for extracellular protein degradation and the potential differentiation of EpiBiologics’ EpiTAC platform.
In financial terms, a successful clinical entry in 2026 could significantly elevate valuation prospects and open pathways toward later-stage financing or strategic exits. The backing from healthcare and tech investors might also create synergies in digital health integration, data analytics, and biomarker discovery — areas of increasing relevance in precision oncology.
FAQ
1. How much funding did EpiBiologics secure in this round?
EpiBiologics raised $107 million in its Series B round.
2. Who led the investment?
The round was co-led by Johnson & Johnson’s venture arm JJDC and Google Ventures.
3. What will the funds be used for?
Primarily to move the lead program EPI-326 into clinical trials and advance the broader pipeline.
4. When are clinical trials expected to begin?
Early 2026 for non-small cell lung cancer and head and neck squamous cell carcinoma indications.
5. Which investors returned from previous rounds?
Polaris Partners, Digitalis Ventures, Taiho Ventures, Vivo Capital, Codon Capital, and Mission BioCapital.
Key takeaways
EpiBiologics’ $107 million Series B shows strong cross-sector investor interest in targeted protein degradation. Founders in biotech can note how strategic alignment between therapeutics expertise and technological investment can unlock substantial funding. Investors may see early-stage momentum that could translate into value inflection if clinical results align with preclinical promise.
Disclaimer
This content is provided for informational purposes only and does not constitute financial advice.